Suppr超能文献

三种不同泼尼松龙前药的药代动力学和药效学:对循环淋巴细胞亚群及功能的影响

Pharmacokinetics and pharmacodynamics of three different prednisolone prodrugs: effect on circulating lymphocyte subsets and function.

作者信息

Frey B M, Walker C, Frey F J, de Weck A L

出版信息

J Immunol. 1984 Nov;133(5):2479-87.

PMID:6237151
Abstract

To be pharmacologically active, i.v. prednisolone disodium phosphate (prednisolone phosphate), prednisolone sodium tetrahydrophthalate (prednisolone phthalate), and oral prednisone have to be converted in vivo into prednisolone. The purpose of the present study was to establish whether these agents are functionally equivalent when given in equimolar doses. The peak concentrations of total and unbound prednisolone assessed by HPLC and equilibrium dialysis in five normal volunteers were five to 12 times higher after i.v. prednisolone phosphate than after i.v. prednisolone phthalate or oral prednisone (p less than 0.001). The area under the plasma concentration vs time curves (AUC) of total and unbound prednisolone was higher after i.v. prednisolone phosphate than after oral prednisone or i.v. prednisolone phthalate (p less than 0.001). The immunosuppressive activity of the plasma samples was determined as the percentage inhibition of the mixed lymphocyte reaction, and the area under the inhibition vs time curve of the MLR (AUIC), a measure of immunosuppressive capacity over time, was calculated. After i.v. prednisolone phthalate or oral prednisone, the mean AUC of unbound prednisolone were 45 and 61% of that obtained after i.v. prednisolone phosphate, and the corresponding AUIC were 76 and 68%, respectively, indicating lower systemic availability of prednisolone and less of an immunosuppressive effect in plasma after i.v. prednisolone phthalate or oral prednisone than after i.v. prednisolone phosphate. These differences in biologic activity of the plasma were corroborated by determining ex vivo the cell cycle progression within the G1 phase, and the interleukin 2 (IL 2) release after the activation of peripheral lymphocytes obtained at various time points after administration of the three steroids. After steroid doses corresponding to 1 mg/kg of prednisolone, a transient inhibition of 80% of IL 2 production was observed with all three glucocorticoids given, whereas the maximal inhibition of the IL 2 production was 60, 30, and 22% after a low dose (0.1 mg/kg) of prednisolone phosphate, prednisone, or prednisolone phthalate, respectively. After the low dose, only minimal changes in the percentages of the OKT4+ and OKT8+ cells were detectable, whereas after the high dose of all three steroids the ratio of OKT4+ to the OKT8+ cells dropped, the decline being more pronounced after prednisolone phosphate than after prednisolone phthalate or prednisone.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

为具有药理活性,静脉注射的磷酸泼尼松龙二钠(泼尼松龙磷酸盐)、四氢邻苯二甲酸泼尼松龙钠(泼尼松龙邻苯二甲酸盐)以及口服的泼尼松必须在体内转化为泼尼松龙。本研究的目的是确定给予等摩尔剂量时这些药物在功能上是否等效。通过高效液相色谱法(HPLC)和平衡透析法评估,在五名正常志愿者中,静脉注射泼尼松龙磷酸盐后总泼尼松龙和游离泼尼松龙的峰值浓度比静脉注射泼尼松龙邻苯二甲酸盐或口服泼尼松后高5至12倍(p<0.001)。静脉注射泼尼松龙磷酸盐后总泼尼松龙和游离泼尼松龙的血浆浓度-时间曲线下面积(AUC)高于口服泼尼松或静脉注射泼尼松龙邻苯二甲酸盐(p<0.001)。血浆样本的免疫抑制活性通过混合淋巴细胞反应的抑制百分比来确定,并计算混合淋巴细胞反应抑制率-时间曲线下面积(AUIC),这是一种衡量随时间的免疫抑制能力的指标。静脉注射泼尼松龙邻苯二甲酸盐或口服泼尼松后,游离泼尼松龙的平均AUC分别为静脉注射泼尼松龙磷酸盐后获得值的45%和61%,相应的AUIC分别为76%和68%,表明静脉注射泼尼松龙邻苯二甲酸盐或口服泼尼松后泼尼松龙的全身可用性较低,血浆中的免疫抑制作用比静脉注射泼尼松龙磷酸盐后小。通过在给药后不同时间点获取的外周淋巴细胞激活后体内测定G1期细胞周期进程以及白细胞介素2(IL-2)释放,证实了血浆生物活性的这些差异。给予相当于1mg/kg泼尼松龙的类固醇剂量后,三种糖皮质激素均观察到IL-2产生的短暂抑制达80%,而低剂量(0.1mg/kg)的泼尼松龙磷酸盐、泼尼松或泼尼松龙邻苯二甲酸盐后IL-2产生的最大抑制分别为60%、30%和22%。低剂量后,仅可检测到OKT4+和OKT8+细胞百分比的微小变化,而三种类固醇高剂量后OKT4+与OKT8+细胞的比例下降,泼尼松龙磷酸盐后的下降比泼尼松龙邻苯二甲酸盐或泼尼松后更明显。(摘要截短于400字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验